manalikamdar
@mana1981
Followers
734
Following
3K
Media
47
Statuses
699
HematoOncologist, eternal optimist, passionate about making every moment count
Denver, CO
Joined October 2009
RT @CUCancerCenter: #BloodCancerAwarenessMonth: The latest study from CU Cancer Center member Manali Kamdar (@mana1981), MD, focuses on CD1….
news.cuanschutz.edu
Research led by a CU Cancer Center member has contributed to a regulatory change that could broaden access to a form of CAR T-cell therapy for lymphoma.
0
2
0
RT @CULymphoma: Welcome to our new @CUHematology faculty Dr. Cassandra Duarte! Dr. Duarte is joining our @CULymphoma program with specializ….
0
2
0
RT @majorajay: Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our n….
0
3
0
RT @MarkHardenCUMed: “It’s a huge win for patients": Research led by @CUCancerCenter member @mana1981, MD, has contributed to a change that….
news.cuanschutz.edu
Research led by a CU Cancer Center member has contributed to a regulatory change that could broaden access to a form of CAR T-cell therapy for lymphoma.
0
5
0
RT @DrRaulCordoba: #Hematology Outcomes of bispecific antibody therapy after #CARTcell failure in relapsed/refractory large B-cell #lymphom….
ashpublications.org
Key PointsEarly relapse after CAR-T (≤3 months) is associated with poor outcome of subsequent BsAb therapy.Lactate dehydrogenase, higher International Prog
0
9
0
RT @tobyeyre82: Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis ht….
ashpublications.org
Key Points. POD post-CAR-T for R/R MCL is associated with short OS and time from CAR-T infusion to POD, predicted inferior OS in this settingBispecific ant
0
16
0
0
1
0
RT @DAVAOnc: Dr. @mana1981 (@CUAnschutz) presented early APOLLO data for MT-601, a non-engineered MAR-T targeting 6 antigens: 78% NHL pts….
0
2
0
RT @vpizzuti44: I am happy to announce I was selected by @ASH_Hematology to receive the ASH HONORS Award!. Excited for this project studyin….
0
6
0
Thrilled to share our 3‑year follow‑up results from the phase III TRANSFORM trial of lisocabtagene maraleucel vs standard of care in 2L R/R LBCL 🎉 @CUCancerCenter @CUHematology @lymphoma @WomenInLymphoma
ascopubs.org
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large...
1
10
55
RT @lymphomaphilia: Mark this Day! Thank you FDA! A major step in increasing access to CAR-T!. In my opinion, 4 weeks was like a sentence,….
targetedonc.com
FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.
0
3
0
RT @majorajay: >1500 trial & @CIBMTR pts who received liso-cel:.- 96-97% of CRS events were before D+15.- 88-95% ICANS before D+15.- no G5….
0
5
0
RT @VJHemOnc: It's always a pleasure to catch up w/ Manali Kamdar (@mana1981) of @CUCancerCenter 😄. At #ASCO25, she provided insight into r….
vjhemonc.com
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses research exploring how to optimize post-CAR T-cell monitoring in patients receiving lisocabtagene maraleucel (liso-cel),...
0
2
0
You made my day James !!! Thank you !!!.
On a personal note, my son wrote a heartfelt thank you to my husband’s amazing med onc, Manali Kamdar @mana1981 to celebrate 5 years NED from DLBCL. She met us at a difficult time right before our son’s birth and guided us expertly and with immense compassion ❤️ @CUCancerCenter
0
3
25
RT @majorajay: Elated to be joining the @ASH_hematology Clinical Research Training Institute (CRTI) in 2025! Eager to work on our research….
0
5
0
RT @majorajay: 2nd myeloid cancers post CD19 CAR @NGazeau14 .- 539 pts, all B-NHL.- 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!).- ⬆️ MC….
0
14
0
RT @CULymphoma: Our @CULymphoma faculty Dr. @majorajay contributed to a multicenter study of venetoclax in relapsed/refractory Waldenstrom….
0
3
0